System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Faiez Zannad is an expert in Cardiology at Centre Hospitalier Universitaire de Nancy (France). As of October 2026, ScienceLeadR ranks Faiez Zannad in the top 1% of experts worldwide for Heart Failure, Reflex and Myocardial Ischemia. Faiez Zannad has authored 1,670 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 2 of them ongoing. SLR score: 6,634 (community average: 125). How the SLR is computed.

LeadR Profile

Faiez Zannad Centre Hospitalier Universitaire de Nancy France
6 634 ScienceLeadR Reputation 6634

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Endocrinology - Nephrology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1987 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1670

Citations

Citations: 197 798 1st author: 139 Last author: 322 Unique author: 52

Main journals

Eur J Heart Fail 250
J Am Coll Cardiol 127
Eur Heart J 126
Circulation 81
JACC Heart Fail 71

Best Journals

Eur Heart J 54
Circulation 36
N Engl J Med 28

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial.
PMID 42776557 — kidney diseases, heart failure, heart, cardiovascular diseases, kidney		JAMA Cardiol20260
MAGGIC and PREDICT-HF Models in the VICTOR Trial: Do Traditional Risk Scores Still Work in Well-Treated Ambulatory Patients with HFrEF?
PMID 42766804 — heart failure, work, heart failure, systolic		Eur J Heart Fail20260
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial.
PMID 42748047 — mortality, disease-free survival, heart failure, probability, heart failure, systolic, actuarial analysis		Eur J Heart Fail20260
Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.
PMID 41762689 — sodium-glucose transporter 2 inhibitors, pyelonephritis, heart failure, heart, infections		Eur J Heart Fail20262
Phenotype-specific prognostic implications of pulse pressure in heart failure.
PMID 42725585 — hospitalization, heart failure, heart, phenotype, heart failure, diastolic, heart failure, systolic, prognosis, pulse		Eur J Heart Fail20260

Clinical Studies 61

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8

By phase:

Phase 3 30
N/A 18
Phase 2 7
Phase 4 4
Phase 2/Phase 3 2

By status:

Completed 51
Active not recruiting 3
Terminated 3
Recruiting 2
Unknown 2

By type:

Interventional 58
Observational 3

By Monocentric/Multicentric:

monocentric 18
multicentric2to4 4
multicentric5to9 3
multicentricup10 36

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Dapagliflozin With or Without Spironolactone for HFpEF
NCT05676684 — diabetes mellitus, sodium-glucose transport proteins, aldosterone, heart failure, heart, heart failure, diastolic, heart failure, systolic, therapeutics, spironolactone		Phase 2/Phase 3Active not recruiting2022
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
NCT05359263 — kidney diseases, double-blind method, kidney, renal insufficiency, renal insufficiency, chronic		Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS